Black Titan (NASDAQ:BTTC – Get Free Report) is one of 48 publicly-traded companies in the “Services – Computer Programming And Data Processing” industry, but how does it compare to its peers? We will compare Black Titan to similar businesses based on the strength of its valuation, analyst recommendations, risk, dividends, earnings, profitability and institutional ownership.
Volatility & Risk
Black Titan has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, Black Titan’s peers have a beta of 0.54, meaning that their average stock price is 46% less volatile than the S&P 500.
Valuation and Earnings
This table compares Black Titan and its peers revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Black Titan | $180,000.00 | -$4.71 million | -0.54 |
| Black Titan Competitors | $250.54 million | -$80.63 million | -9.74 |
Profitability
This table compares Black Titan and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Black Titan | N/A | -108.60% | -95.64% |
| Black Titan Competitors | -63.65% | -919.53% | -68.53% |
Insider and Institutional Ownership
56.4% of shares of all “Services – Computer Programming And Data Processing” companies are held by institutional investors. 0.7% of Black Titan shares are held by company insiders. Comparatively, 16.4% of shares of all “Services – Computer Programming And Data Processing” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings for Black Titan and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Black Titan | 1 | 0 | 0 | 0 | 1.00 |
| Black Titan Competitors | 99 | 204 | 221 | 14 | 2.28 |
As a group, “Services – Computer Programming And Data Processing” companies have a potential upside of 118.30%. Given Black Titan’s peers stronger consensus rating and higher possible upside, analysts plainly believe Black Titan has less favorable growth aspects than its peers.
Summary
Black Titan peers beat Black Titan on 8 of the 13 factors compared.
Black Titan Company Profile
Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.
Receive News & Ratings for Black Titan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Titan and related companies with MarketBeat.com's FREE daily email newsletter.
